For instance, GLUT1 inhibitors (e.g., Ritonavir, Fasentin), hexokinase inhibitors (e.g., Ionidamine, 3-BrPA), PKM2 inhibitors (e.g., OA, TT-232, VK3, VK5), and PDK1 inhibitor (DCA) are metabolic inhibitors that have been evaluated in a variety of cancer types with Warburg phenotype [134]. Here, SLC2A1 is linked to cancer.